CURA has lost 15% over the past month and nearly 10% in the past week alone, making it one of the sharper decliners in a cannabis peer group that is broadly under pressure — the question now is whether the stock is being dragged down by sector sentiment or whether something more specific is at work.
The broader cannabis space is moving in lockstep to the downside. TSND fell 10% on the week and CL dropped nearly 7%, while GTII shed 6%. WEED and TLRY held up better, losing around 3-5%. Curaleaf's weekly decline of 9.5% puts it in the weaker half of the group, though not dramatically so — the sector is simply in retreat across the board, with no single name bucking the trend meaningfully.
The lending market offers no real signal here. Borrow availability is extraordinarily loose at over 1,300% — meaning there are roughly thirteen shares available to lend for every one currently borrowed. Short interest is negligible at just 0.24% of free float, and even after a 7% week-on-week uptick in shares short, the absolute level is too small to move the needle. Cost to borrow has crept up 39% over the week to 2.07%, but from a very low base — this is not a name where the borrow market tells a meaningful story about conviction from either side.
The ownership picture carries more texture. AdvisorShares nearly doubled its position in the most recent reporting period, adding 18 million shares to hold 10.7% of the company — a substantial concentration in a single ETF issuer. Meanwhile, insider activity has been one-directional: the Chief Legal Officer made multiple open-market sales in late June and early July, and an unnamed President sold 82,000 shares around CAD 9.23 on June 24, all with low trade significance scores. Net insider activity over 90 days is modestly positive in share count terms, boosted by equity award grants to directors on June 22, but the cash transactions are sales. That divergence — institutional accumulation alongside insider disposal — is worth noting without overreading it.
The ORTEX stock score has been range-bound near 33, well below its January high of 39. One genuine bright spot is the quality pillar: the Piotroski F-score has improved from 4 to 6 over the past six months, return on assets has moved from 0.13 to 0.24, and free cash flow to assets remains positive. EPS momentum over 30 days ranks in the 90th percentile — a strong reading — but the EPS surprise score is a lowly 4th percentile and forward estimates remain deeply negative, keeping the growth story subdued. The next earnings event is scheduled for August 5, which makes that print the next concrete opportunity to test whether the improving cash-generation story is translating into numbers the Street will reward.
See the live data behind this article on ORTEX.
Open CURA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
